Probiotic-based therapy for pulmonary arterial hypertension (PAH): Probiotic Lactobacillus Rhamnosus inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 15/November/2018, 10.48 pm

Molecular therapy for safeguarding your heart against cardiac dysfunction: Canagliflozin (trade name: Invokana or Sulisent), a drug used in the treatment of TIIDM,  decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 15/November/2018, 10.02 pm
November 15, 2018
Molecular therapy for cardiac dysfunction: Empagliflozin (trade name: Jardiance), used in the treatment of TIIDM, decreases Mir-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 15/November/2018, 11.22 pm
November 15, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based therapy for pulmonary arterial hypertension (PAH): Probiotic Lactobacillus Rhamnosus inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3


The significance of the study:  

This study suggests, for the first time, that Probiotic Lactobacillus Rhamnosusby increasing the expression of its target gene, it may decrease, in a dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing “Probiotic Lactobacillus Rhamnosuseither alone or in combination with other drugs,” may be used to treat pulmonary arterial hypertension (Figure 2).

Figure 1. Mechanistic insights into how Probiotic Lactobacillus Rhamnosus inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 1. Mechanistic insights into how Probiotic Lactobacillus Rhamnosus inhibits the development of pulmonary hypertension through regulation of its target genes


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How Probiotic Lactobacillus Rhamnosus decrease the expression of Notch3 and its target gene?

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Probiotic-based therapy for pulmonary arterial hypertension (PAH): Probiotic Lactobacillus Rhamnosus inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 15/November/2018, 10.48 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.